GSK news live: sideways-to-upward bias forecast with strong support at Ichimoku Kijun

Traders Union
All News
Financial News
GSK slides 0.78% today to GBX 1,773

Highlights

GSK advanced its share buyback program by purchasing 185,000 ordinary shares, raising its treasury holding to 234,819,844 shares.
GSK transferred 22 million treasury shares to an employee trust for incentive plans and disclosed director acquisitions of American Depositary Shares via dividend reinvestment.
Growth drivers include a £45 million partnership with the Fleming Initiative and Imperial targeting AMR with advanced AI, alongside the recent completion of the BELLUS Health acquisition.

Buybacks and partnerships drive capital allocation and strategic growth

GSK has advanced its ongoing share buyback program, purchasing 185,000 ordinary shares to be held in treasury, bringing the total in treasury to 234,819,844. The company also transferred 22 million treasury shares to an employee trust for incentive plans and reported director acquisitions of American Depositary Shares through dividend reinvestment. Additional drivers include GSK's £45 million partnership with the Fleming Initiative and Imperial targeting AMR via advanced AI, and the recently completed acquisition of BELLUS Health.

Bullish momentum persists amid mixed technical signals and overbought warning

GBX 1,773.00 trades above the MA-20 (GBX 1,750.05), MA-50 (GBX 1,638.56), and MA-200 (GBX 1,486.67), confirming a bullish structure across short-, medium-, and long-term trends. Nearest dynamic support sits at the Ichimoku Kijun (GBX 1,713.25), while resistance is now defined by the MA-20 and round-number levels above. Momentum indicators on the daily chart show bullish conviction, with MACD delivering a strong buy signal and ADX at 27.91 confirming a supportive trend environment. However, Stochastic RSI flags oversold, while daily RSI and CCI hover in neutral-to-mild buy territory, and BBP’s overbought reading indicates buyers have recently dominated but may be losing steam. The Awesome Oscillator remains neutral.

Range-bound outlook with high upside bias as momentum supports gains

For the next five sessions, expect a range of approximately GBX 1,765.00 to GBX 1,790.00, with sideways-to-slightly upward bias. The probability of a price increase is very high (more than 80%), with a much lower likelihood of a decline. In the baseline scenario, prices hold steady within this corridor as trend momentum keeps buyers engaged. Bullish continuation requires a break above GBX 1,790.00, opening the way for higher targets if momentum persists. Conversely, a drop below GBX 1,765.00 would signal renewed selling, with the Ichimoku Kijun acting as a key support to watch in the coming week.

Viktoras Karapetjanc, analyst at Traders Union, highlights GSK’s resilient bullish structure, underpinned by solid fundamentals and robust institutional actions such as ongoing buybacks and strategic acquisitions. He sees strong sentiment supported by positive momentum indicators and targeted partnerships, especially given the company’s proactive engagement against AMR. Tactical risk remains limited while GBX 1,765.00 holds as support. Karapetjanc believes upward bias will persist as long as momentum and fundamentals remain aligned. "If GSK maintains this trajectory, I expect buyers to stay in control and a run beyond GBX 1,790.00 is well within reach."

Previously it was noted that GSK continued its share buyback activity and formed a new partnership to advance tuberculosis treatment. The technical analysis discussed overbought momentum alongside robust trend based on market signals.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.